Finance

B-cells in multiple myeloma
#Acquisition #Bispecific Antibodies #Dren Bio #Finance #Immunology #Sanofi

Bi-specific antibody acquisition broadens immunology pipeline

Sanofi and Dren Bio, a clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies. DR-0201 is a potential first-in-class CD20-directed bispecific antibody that… Read More

#Business & Investment #News

#Collaboration #Deep Science Ventures #Fibrosis #Finance #General Inception #Therapeutics

Venture partners create fibrosis-focused therapeutics company

Venture studios Deep Science Ventures and General Inception have announced plans to create a company focused on developing novel treatments for fibrosis. Science Ventures and General Inception’s European arm, Igniter Europe, aim to establish a company dedicated to overcoming current bottlenecks in fibrosis therapeutics by developing a novel concept and… Read More

#Business & Investment #News

#Finance #Funding #Investment #Neurodegenerative disorders #Neuroscience #Private investment

New DDW Highlights episode: 11 November 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In a week that saw a second monoclonal antibody rejected by UK regulator NICE,… Read More

#News

#Finance #Funding #Investment #Neurodegenerative disorders #Neuroscience #Private investment

This week in drug discovery (4-8 November) 

News round-up for 4-8 November by DDW Senior Digital Content Editor Diana Spencer. This week DDW has reported on significant investment in the development of treatments for neurodegenerative diseases, but also gene therapies for CNS disorders and radioligand-based therapies for cancer. The top stories:… Read More

#News

#Finance #Funding #Investment #Politics #Private investment #UK government

New DDW Highlights episode: 4 November 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In a week that saw a second monoclonal antibody rejected by UK… Read More

#News

#Finance #Funding #Investment #Politics #Private investment #UK government

This week in drug discovery (28 Oct – 1 Nov) 

News round-up for 28 Oct – 1 Nov by DDW Senior Digital Content Editor Diana Spencer. In a week that saw a second monoclonal antibody rejected by UK regulator NICE, antibodies have been high on the news agenda. More positively, a new indication for Fasenra was approved in… Read More

#News

#Finance #Funding #Investment #Politics #Private investment #UK government

New DDW Highlights episode: 29 October 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With a presidential election just round the corner in the US and… Read More

#News

#Finance #Funding #Investment #Politics #Private investment #UK government

This week in drug discovery (21-25 October) 

News round-up for 21-25 October by DDW Senior Digital Content Editor Diana Spencer. With a presidential election just round the corner in the US and a new UK budget on the way, financial support for life sciences is high on the agenda, so the news round-up this week… Read More

#News

GBP pound sterling funding
#Biopharmaceuticals #Biotechnology #Finance #Investment #mRNA #Novo Holdings #Oxford Nanopore Technologies

Investing in a new generation of molecular analysis technology 

Novo Holdings has announced a £5 million investment in Oxford Nanopore Technologies as part of an equity issue and intends to add to this investment over time, with further purchases in the secondary market, subject to availability and price (among other factors).  Oxford Nanopore has developed a… Read More

#Business & Investment #News

#FDA #Finance #GlobalData #Minerva Biosciences #Neuroscience #Schizophrenia

Minerva value plummets following FDA rejection of roluperidone

The stock market value of Minerva Biosciences has dropped nearly 60%, following the US Food and Drug administration (FDA) decision not to approve roluperidone for symptoms of schizophrenia. The company received a ‘Complete Response Letter’ from the FDA highlighting the clinical deficiencies in its new drug… Read More

#News #Trending News

GBP pound sterling funding
#Alentis Therapeutics #Curve Therapeutics #Drug discovery #Finance #Funding #Pfizer Ventures #Seed funding #Solid tumours

£40.5 million invested in discovery platform and to advance pipeline 

Curve Therapeutics, a company developing an intracellular screening platform to address disease targets, has completed a £40.5 million ($51.37 million) Series A financing round. Pfizer Ventures led the round with participation from Columbus Venture Partners and British Patient Capital, which join founding investor Advent Life Sciences and… Read More

#News

Bill & Melinda Gates Foundation
#Bill & Melinda Gates Foundation #Drug development #Drug discovery #Finance #Funding #Mouse models #PhaSER Biomedical (PhaSER)

$2.3m Gates Foundation grant to accelerate global drug discovery 

Edinburgh-based PhaSER Biomedical (PhaSER) has received a Bill & Melinda Gates Foundation grant totalling $2.3m to continue its work in accelerating drug discovery and development.   PhaSER will provide 8HUM transgenic mouse models, humanised for key pathways involved in the metabolism and disposition of drugs, to all the… Read More

#News

#Collaboration #Dermatology #Finance #Funding #Immuno-dermatology #Medicxi

$100M financing to advance immuno-dermatology pipeline 

Alys Pharmaceuticals has launched with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi. The company originates from the aggregation of six Medicxi companies.  Co-founded by Medicxi and several dermatology and scientific experts, including John Harris (UMass Chan Medical School), Brian… Read More

#Business & Investment #News

UK on global map
#BioIndustry Association #Biologics / Biotechnology #Equity finance #Finance #Fundraising #Investment #Life sciences #Market reporting #Private investment #Seed funding #UK

UK remains strongest biotech hub in Europe despite general decline

After a disappointing start to the year, the last few months have seen a boost to fundraising for UK biotech companies. DDW’s Diana Spencer unpacks the Q3 figures and annual predictions from the BioIndustry Association1.  While 2021 was the highest year on record for… Read More

#Business & Investment #Exclusive Content #Market Reports

#Collaboration #CRISPR #CRISPR-Cas9 #Cystic fibrosis #Finance #Gene editing #Liver disease #Neuropsychiatric disorders #Oncology #RNA

This week in drug discovery (10-14 October)

News round-up for 10-14 October by DDW Digital Content Editor Diana Spencer The top news in the world of drug discovery this week reflects the vital importance of collaboration, partnership and support within this industry.  Partnerships… Read More

#News